R&D pipeline

1.Development stage and area

Region Exploratory Clinical Study
Phase 2
Confirmatory Clinical Study
Phase 3
NDA filed
Japan

Y-39983
<Glaucoma>

Difluprednate
<DME>

 

Brimonidine
<Glaucoma>
Approved

USA
EU
     
Asia    

Tacrolimus<VKC>
Pimaricin<Infection>
China

2.Product information

DrugCode nameDosage FormMechanisum of actionIndication
Brimonidine tartrateSNJ-2022Topical ophthalmic solutionAlpha-2 adrenergic agonistGlaucoma
Y-39983SNJ-1656Topical ophthalmic solutionRho kinase inhibitorGlaucoma
Tacrolimus FK 506 Topical ophthalmic suspension Ccalcineurin inhibitor Vernal keratoconjunctivitis (VKC)
Difluprednate SJE-2079 Topical ophthalmic emulsion Corticosteroid Diabetic macular edema (DME)

3.Additional information

Brimonidine tartrateBrimonidine tartrate has a dual mechanism of action by reducing aqueous humor production and increasing uveoscleral outflow.
BAC-free formulation.
Y-39983Y-39983 has a mechanism of action by increasing outflow of aqueous humor through the trabecular mechwork.
Tacrolimus Tacrolimus is an immunosuppressive drug, and reduces cytokine production by T-cells.
It has an excellent clinical effect against vernal keratoconjunctivitis as well as steriods.
Difluprednate Difluprednate eye drop is a corticosteroid which has strong anti-inflammatory effect.
Penetration of the drug into the eye is increased by unique emulsification technology.